Liver function may change how anxiety drug works

NCT ID NCT07457190

Not yet recruiting Knowledge-focused Sponsor: Beijing Union Pharmaceutical Factory Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study looks at how the drug buagafuran (AF-5) behaves in people with liver impairment compared to those with normal liver function. Twenty-four adults will receive a single 30 mg dose, and researchers will measure drug levels in the blood and monitor safety. The goal is to understand if liver problems affect how the drug is processed, which could guide future dosing for anxiety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Buagafuran (AF-5)
What this could lead to: If successful, this study could help determine safe dosing of buagafuran for people with liver problems who have anxiety.
What could go wrong: This is a very early, small Phase 1 study focused on safety and drug levels, not on treating anxiety. It may not lead to any treatment benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED ANXIETY DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

generalized anxiety disorder liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED ANXIETY DISORDER

Contacts and locations

Locations

Beijing Union Pharmaceutical Factory Ltd

Beijing, Beijing Municipality, 102600, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.